Making your decision: the practical framework After reviewing all the dosage data, side effects, timelines, and mechanisms, the decision between retatrutide and tirzepatide comes down to a handful of practical questions
Conclusion This comprehensive review highlights the therapeutic potential of GLP-1 and its analogs in the management of metabolic disorders, particularly T2DM
Phase III results for retatrutide are set to be released later in 2025 and in early 2026, but an earlier phase II trial recorded between a 7.2% and 17.5% reduction in body weight after 24 weeks, depending on the dose (7.2% on 1mg, 17.5% on 12mg), and up to a 24.2% reduction in body weight after 48 weeks for those on 12mg (-8.7% change for those on 1mg) 8
Current testing status, available Certificates of Analysis, and verification details are maintained on our Third-Party Testing & Certificates of Analysis page
Retatrutide Hair Loss: Prevention & Fix Does retatrutide cause hair loss
Novo Nordisk released Victoza in 2010, then Ozempic in 2017, a once-weekly injection that became a blockbuster
